Cibus director Gerhard Prante sells $2,817 in stock

SAN DIEGO—Cibus, Inc. (NASDAQ:CBUS) Director Gerhard Prante has recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Prante sold 1,150 shares of Class A Common Stock on February 12, 2025, at a price of $2.45 per share. This transaction amounts to a total value of $2,817. The sale price represents a significant decline from the stock’s 52-week high of $23.18, reflecting the company’s challenging year which saw an 86% decline in share value. InvestingPro analysis indicates the stock may be undervalued at current levels.

Following this transaction, Prante holds 18,057 shares in Cibus. The sale was conducted under a pre-established Rule 10b5-1 trading plan, which was adopted on August 16, 2024. This plan allows insiders to set up a predetermined schedule for selling stocks, providing a degree of separation from potential market manipulation concerns. For comprehensive insider trading analysis and 12 additional key insights about Cibus, visit InvestingPro.

Cibus, headquartered in San Diego, operates in the agriculture chemicals sector, focusing on innovative solutions to enhance crop productivity. With a market capitalization of $85.79 million, analysts maintain a positive outlook, setting price targets ranging from $4 to $25 per share.

In other recent news, Cibus has been the focus of several significant developments. Canaccord Genuity analysts have revised their outlook on Cibus, reducing the stock’s price target from $20.00 to $18.00, but maintaining a Buy rating. This follows Cibus’s announcement of a direct stock offering, intended to raise approximately $22.6 million for the advancement of its gene-edited plant productivity traits and the further development of its soybean platform.

In addition to financial adjustments, Cibus has also approved a new base salary for executive Carlo Broos. The Compensation Committee of Cibus’s Board of Directors has set a base salary of $320,000 for Mr. Broos, as disclosed in a recent filing with the Securities and Exchange Commission. Details of the previous salary or the percentage increase represented were not provided.

Lastly, Jefferies has also adjusted its price target for Cibus, lowering it to $5.00 from $8.00, while maintaining a Hold rating. This decision was made in light of Cibus’s careful management of its balance sheet and its potential to enhance its negotiating stance if the European Union approves gene editing. Cibus’s path to reaching free cash flow breakeven is contingent upon the successful development of either a soy or wheat trait, or the ability to get its product across 2 to 5 million acres.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.